• Users Online:10
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2012  |  Volume : 6  |  Issue : 4  |  Page : 8-15

A multicentric, double-blind randomized, homoeopathic pathogenetic trial of Caesalpinia bonducella

1 Central Council for Research in Homoeopathy, New Delhi, India
2 Drug Proving Research Unit of Homoeopathy, KolKata, India
3 Homoeopathic Drug Research Institute, Lucknow, India
4 Drug Proving Unit (Homoeopathy), Bhubaneswar, India

Correspondence Address:
Scientist-4 Central Council for Research in Homoeopathy, 61-65, Institutional Area, Janakpuri, New Delhi- 110 058
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Objective:To elicit the pathogenetic response of Caesalpinia bonducella in homoeopathic potencies on healthy human volunteers. Methodology:The drug Caesalpinia bonducella was proved by the Central Council for Research in Homoeopathy (CCRH) through randomized, double-blind, placebo-controlled design. The proving was conducted at three centres. The drug was proved in 6 & 30 centesimal potencies on 50 apparently healthy volunteers, declared eligible after their pre-trial medical examinations by the medical specialists and routine laboratory investigations. In first phase of proving, provers were given 56 doses of placebo divided in 04 doses per day for 14 days. In next two phases, 56 doses of pre-selected potencies or placebo as per the randomization were administered in divided doses same as in first phase. The symptoms manifested during the trial period were noted down by the provers and elaborated by the Proving Masters. The generated data of the drug from all three centres were compiled at provingcum- data processing cell of CCRH headquarters after de-coding. Observations:Out of 34 provers who were on actual drug trial, only 12 manifested symptoms. Drug was able to manifest symptoms in both the potencies, in more or less every part of the body. Conclusion:The pathogenetic response elicited during the proving trial, expands the scope of use of the drug Caesalpinia bonducella and will benefit the research scholars and clinicians. The generated symptoms of this drug will carry more value when verified clinically.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded1005    
    Comments [Add]    

Recommend this journal